322 related articles for article (PubMed ID: 28495913)
41. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
[TBL] [Abstract][Full Text] [Related]
42. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
[TBL] [Abstract][Full Text] [Related]
43. Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma.
Şeyhanlı A; Yavuz B; Akşit Z; Yüce Z; Özkal S; Altungöz O; Demirkan F; Alacacıoğlu İ; Özsan GH
Turk J Haematol; 2022 Jun; 39(2):109-116. PubMed ID: 34823323
[TBL] [Abstract][Full Text] [Related]
44. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
45. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
[TBL] [Abstract][Full Text] [Related]
46. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
47. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
48. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
49. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
50. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.
Hamdaoui H; Benlarroubia O; Ait Boujmia OK; Mossafa H; Ouldim K; Belkhayat A; Smyej I; Benrahma H; Dehbi H; Chegdani F
Mol Genet Genomic Med; 2020 Sep; 8(9):e1363. PubMed ID: 32573970
[TBL] [Abstract][Full Text] [Related]
51. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
[TBL] [Abstract][Full Text] [Related]
52. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
[TBL] [Abstract][Full Text] [Related]
53. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
54. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
55. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience.
Jung HA; Jang MA; Kim K; Kim SH
Ann Lab Med; 2018 May; 38(3):196-203. PubMed ID: 29401553
[TBL] [Abstract][Full Text] [Related]
56. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation.
Lee CK; Zangari M; Fassas A; Thertulien R; Talamo G; Badros A; Cottler-Fox M; van Rhee F; Barlogie B; Tricot G
Bone Marrow Transplant; 2006 Mar; 37(5):511-5. PubMed ID: 16435020
[TBL] [Abstract][Full Text] [Related]
57. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
58. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
59. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma.
Srour SA; Saliba RM; Bashir Q; Popat UR; Ahmed S; Mehta RS; Delgado R; Rondon G; Parmar S; Kebriaei P; Hosing C; Manasanch EE; Lee HC; Patel KK; Orlowski RZ; Shpall E; Champlin RE; Qazilbash MH; Nieto Y
Transplant Cell Ther; 2021 Mar; 27(3):243.e1-243.e6. PubMed ID: 33781521
[TBL] [Abstract][Full Text] [Related]
60. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
